

Brigitte C Widemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6797175/publications.pdf>

Version: 2024-02-01

201
papers

10,007
citations

30047

54
h-index

42364

92
g-index

205
all docs

205
docs citations

205
times ranked

10753
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding and Managing Methotrexate Nephrotoxicity. <i>Oncologist</i> , 2006, 11, 694-703.	1.9	591
2	Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2016, 375, 2550-2560.	13.9	486
3	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , 2017, 31, 833-843.e5.	7.7	383
4	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	13.9	360
5	Low-Intensity Therapy in Adults with Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1915-1925.	13.9	307
6	Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. <i>Human Pathology</i> , 2017, 67, 1-10.	1.1	275
7	MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. <i>Journal of Clinical Investigation</i> , 2013, 123, 340-347.	3.9	273
8	High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. <i>Cancer</i> , 2004, 100, 2222-2232.	2.0	271
9	Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. <i>Neuro-Oncology</i> , 2008, 10, 593-598.	0.6	200
10	Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. <i>Arthritis and Rheumatism</i> , 2012, 64, 2375-2386.	6.7	182
11	Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2006, 24, 507-516.	0.8	139
12	Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4239-4248.	3.2	136
13	Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. <i>Journal of Clinical Oncology</i> , 2016, 34, 3031-3038.	0.8	132
14	Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 3979-3986.	0.8	130
15	Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days. <i>Journal of Clinical Oncology</i> , 2003, 21, 1866-1873.	0.8	127
16	High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. <i>Journal of Pediatrics</i> , 1992, 121, 93-97.	0.9	123
17	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , 2018, 23, 52-61.	1.9	123
18	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2015, 17, 596-603.	0.6	118

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. <i>Genetics in Medicine</i> , 2019, 21, 1189-1198.	1.1	115
20	Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. <i>Blood</i> , 2008, 111, 566-573.	0.6	113
21	Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. <i>Current Oncology Reports</i> , 2009, 11, 322-328.	1.8	110
22	Recommendations for imaging tumor response in neurofibromatosis clinical trials. <i>Neurology</i> , 2013, 81, S33-40.	1.5	107
23	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2012, 18, 6011-6022.	3.2	103
24	Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. <i>Clinical Cancer Research</i> , 2012, 18, 2099-2107.	3.2	103
25	Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 75.	1.2	99
26	MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. <i>Clinical Cancer Research</i> , 2016, 22, 3810-3820.	3.2	99
27	A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan-VEGF Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 5174-5181.	0.8	98
28	Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. <i>Journal of Clinical Oncology</i> , 2018, 36, 160-167.	0.8	94
29	Phase I Trial and Pharmacokinetic Study of Lixtatumumab in Pediatric Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 4141-4147.	0.8	93
30	Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Neuro-Oncology</i> , 2014, 16, 707-718.	0.6	93
31	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	0.8	92
32	Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. <i>Sarcoma</i> , 2017, 2017, 1-10.	0.7	84
33	The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. <i>Neuro-Oncology</i> , 2018, 20, 818-825.	0.6	83
34	Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. <i>Frontiers in Oncology</i> , 2014, 4, 324.	1.3	80
35	Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	80
36	Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. <i>Blood</i> , 2018, 132, 662-666.	0.6	80

#	ARTICLE	IF	CITATIONS
37	Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1598-1602.	0.8	78
38	Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. <i>Computerized Medical Imaging and Graphics</i> , 2004, 28, 257-265.	3.5	75
39	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. <i>Clinical Cancer Research</i> , 2009, 15, 5032-5039.	3.2	74
40	Sirolimus for nonâ€progressive NF1â€associated plexiform neurofibromas: An NF clinical trials consortium phase II study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 982-986.	0.8	73
41	Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas. <i>Pediatric Neurology</i> , 2007, 36, 293-300.	1.0	72
42	Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, socialâ€emotional functioning, and quality of life. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 2103-2113.	0.7	72
43	Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1â€associated atypical neurofibromas. <i>Neuro-Oncology</i> , 2019, 21, 981-992.	0.6	69
44	Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1. <i>Ophthalmology</i> , 2017, 124, 123-132.	2.5	68
45	Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. <i>Pediatric Blood and Cancer</i> , 2013, 60, 396-401.	0.8	67
46	Efficacy of Glucarpidase (Carboxypeptidase <sc>G</sc>2) in Patients with Acute Kidney Injury After Highâ€Dose Methotrexate Therapy. <i>Pharmacotherapy</i> , 2014, 34, 427-439.	1.2	64
47	Vincristine Sulfate Liposomes Injection (VSLI, MarqiboÂ®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. <i>Pediatric Blood and Cancer</i> , 2016, 63, 997-1005.	0.8	64
48	Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. <i>Cancer</i> , 1995, 76, 521-526.	2.0	63
49	Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1562-1566.	0.8	63
50	Social-emotional Functioning of Children and Adolescents With Neurofibromatosis Type 1 and Plexiform Neurofibromas: Relationships With Cognitive, Disease, and Environmental Variables. <i>Journal of Pediatric Psychology</i> , 2012, 37, 713-724.	1.1	62
51	Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1557-1559.	3.0	60
52	Preclinical testing of Sorafenib and RAD001 in the <i>Nf</i>^{<i>flox/flox</i>}<i>DhhCre</i></sup> mouse model of plexiform neurofibroma using magnetic resonance imaging. <i>Pediatric Blood and Cancer</i> , 2012, 58, 173-180.	0.8	60
53	Achieving consensus for clinical trials. <i>Neurology</i> , 2013, 81, S1-5.	1.5	59
54	Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. <i>American Journal of Human Genetics</i> , 2019, 104, 484-491.	2.6	56

#	ARTICLE	IF	CITATIONS
55	SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. <i>Sarcoma</i> , 2017, 2017, 1-8.	0.7	55
56	Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials. <i>Oncologist</i> , 2008, 13, 679-689.	1.9	54
57	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 645-652.	1.1	54
58	Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. <i>Neuro-Oncology</i> , 2018, 20, 1643-1651.	0.6	54
59	Sorafenib and Sunitinib. <i>Oncologist</i> , 2009, 14, 800-805.	1.9	52
60	¹⁸ F-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). <i>Pediatric Blood and Cancer</i> , 2013, 60, 59-64.	0.8	52
61	Validity, specificity, feasibility and acceptability of a brief pediatric distress thermometer in outpatient clinics. <i>Psycho-Oncology</i> , 2017, 26, 461-468.	1.0	51
62	A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27077.	0.8	49
63	Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. <i>Communications Biology</i> , 2018, 1, 158.	2.0	49
64	Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1273-1283.	1.1	48
65	Successful Treatment of Intrathecal Methotrexate Overdose by Using Ventriculolumbar Perfusion and Intrathecal Instillation of Carboxypeptidase G2. <i>Mayo Clinic Proceedings</i> , 1996, 71, 161-165.	1.4	47
66	Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1397-1406.	3.2	46
67	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	15.2	46
68	Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 7646-7653.	0.8	45
69	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4882-4887.	3.2	45
70	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1111-1115.	3.2	45
71	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). <i>Sarcoma</i> , 2019, 2019, 1-8.	0.7	45
72	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 629-636.	0.8	43

#	ARTICLE	IF	CITATIONS
73	Dihydrofolate Reductase Enzyme Inhibition Assay for Plasma Methotrexate Determination Using a 96-Well Microplate Reader. <i>Clinical Chemistry</i> , 1999, 45, 223-228.	1.5	41
74	Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2010, 16, 750-754.	3.2	41
75	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. <i>Neuro-Oncology</i> , 2017, 19, now158.	0.6	41
76	Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1462-1470.	0.7	41
77	Advancing <sc>RAS/RASopathy</sc> therapies: An NCI-sponsored intramural and extramural collaboration for the study of <sc>RASopathies</sc>. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 866-876.	0.7	40
78	Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas. <i>Clinical Cancer Research</i> , 2009, 15, 7361-7367.	3.2	38
79	Airway endoscopy in the diagnosis and treatment of bacterial tracheitis in children. <i>International Journal of Pediatric Otorhinolaryngology</i> , 1993, 27, 147-157.	0.4	37
80	Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 275-282.	1.1	37
81	Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. <i>Neuro-Oncology</i> , 2020, 22, 1368-1378.	0.6	37
82	Development and Validation of the English Pain Interference Index and Pain Interference Index-Parent Report. <i>Pain Medicine</i> , 2015, 16, 367-373.	0.9	36
83	Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. <i>PLoS Medicine</i> , 2021, 18, e1003734.	3.9	35
84	Current status of MEK inhibitors in the treatment of plexiform neurofibromas. <i>Child's Nervous System</i> , 2020, 36, 2443-2452.	0.6	33
85	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sunitinib in Combination with Ganetespib (SARC023). <i>Sarcoma</i> , 2020, 2020, 1-8.	0.7	33
86	The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. <i>Journal of Neuro-Oncology</i> , 2008, 87, 165-171.	1.4	31
87	Genetic Modifiers of Neurofibromatosis Type 1-Associated Café-au-Lait Macule Count Identified Using Multi-platform Analysis. <i>PLoS Genetics</i> , 2014, 10, e1004575.	1.5	31
88	Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging. <i>Journal of Neuro-Oncology</i> , 2015, 121, 209-215.	1.4	31
89	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	0.6	30
90	The Bioavailability of Oral Methotrexate in Children with Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 445-449.	0.9	29

#	ARTICLE	IF	CITATIONS
91	Cephalometry in adults and children with neurofibromatosis type 1: Implications for the pathogenesis of sphenoid wing dysplasia and the "NF1 facies". <i>European Journal of Medical Genetics</i> , 2015, 58, 584-590.	0.7	29
92	Management of neurofibromatosis type 1-associated plexiform neurofibromas. <i>Neuro-Oncology</i> , 2022, 24, 1827-1844.	0.6	29
93	Puberty and Plexiform Neurofibroma Tumor Growth in Patients with Neurofibromatosis Type I. <i>Journal of Pediatrics</i> , 2014, 164, 620-624.	0.9	28
94	SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10503-10503.	0.8	28
95	Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 332-337.	1.0	27
96	Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium. <i>Pediatric Blood and Cancer</i> , 2015, 62, 45-51.	0.8	27
97	The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex TM) in a nonhuman primate model. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 439-443.	1.1	26
98	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Clinical Cancer Research</i> , 2018, 24, 753-765.	3.2	26
99	Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10018-10018.	0.8	26
100	A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 865-869.	0.8	25
101	Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. <i>ISRN Radiology</i> , 2013, 2013, 1-9.	1.2	24
102	A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. <i>Clinical Cancer Research</i> , 2005, 11, 1247-52.	3.2	24
103	Conclusions and future directions for the REINS International Collaboration. <i>Neurology</i> , 2013, 81, S41-4.	1.5	23
104	The Relationship Between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1. <i>Pain Practice</i> , 2018, 18, 969-978.	0.9	23
105	Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. <i>Molecular Pharmacology</i> , 2019, 96, 158-167.	1.0	23
106	Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma. <i>Blood</i> , 2015, 126, 472-472.	0.6	22
107	Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 56, 226-233.	0.8	21
108	Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 550-556.	0.8	20

#	ARTICLE	IF	CITATIONS
109	The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. <i>Investigational New Drugs</i> , 2012, 30, 524-528.	1.2	20
110	Chordoma: Current status, problems, and future directions. <i>Current Problems in Cancer</i> , 2021, 45, 100771.	1.0	20
111	Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children's Oncology Group Study. <i>Blood</i> , 2005, 106, 2587-2587.	0.6	20
112	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
113	SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). <i>Journal of Clinical Oncology</i> , 2013, 31, 10522-10522.	0.8	19
114	¹¹¹ In-Octreotide Scintigraphy for Identification of Metastatic Medullary Thyroid Carcinoma in Children and Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E207-E212.	1.8	18
115	Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1). <i>Journal of Genetic Counseling</i> , 2018, 27, 115-123.	0.9	18
116	Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. <i>Pediatric Blood and Cancer</i> , 2015, 62, 603-610.	0.8	17
117	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Academic Radiology</i> , 2018, 25, 144-152.	1.3	17
118	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 737-743.	1.1	16
119	Bone mineral density in children and young adults with neurofibromatosis type 1. <i>Endocrine-Related Cancer</i> , 2012, 19, 817-825.	1.6	16
120	Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. <i>Investigational New Drugs</i> , 2016, 34, 61-65.	1.2	16
121	Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years. <i>Journal of Pediatrics</i> , 2018, 203, 447-449.	0.9	16
122	Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. <i>Neurology</i> , 2016, 87, S13-20.	1.5	15
123	Cushing disease in a patient with multiple endocrine neoplasia type 2B. <i>Journal of Clinical and Translational Endocrinology: Case Reports</i> , 2017, 4, 1-4.	0.4	15
124	Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 7-12.	1.8	15
125	The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa095.	0.4	15
126	A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. <i>Oncologist</i> , 2020, 25, 532-540.	1.9	15

#	ARTICLE	IF	CITATIONS
127	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	0.6	14
128	Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 977-984.	1.1	14
129	Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. <i>Neurology: Genetics</i> , 2021, 7, e616.	0.9	14
130	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. <i>Neuro-Oncology</i> , 2022, 24, 1978-1988.	0.6	14
131	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	3.2	13
132	Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2020, 26, 6112-6121.	3.2	13
133	Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute. <i>Contemporary Clinical Trials</i> , 2011, 32, 10-15.	0.8	12
134	Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 923-928.	1.1	12
135	A molecular basis for neurofibroma-associated skeletal manifestations in NF1. <i>Genetics in Medicine</i> , 2020, 22, 1786-1793.	1.1	12
136	Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3612-3612.	0.8	12
137	Creating a comprehensive research strategy for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S1-S4.	1.5	11
138	Clinical trial design for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S31-S37.	1.5	11
139	Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27987.	0.8	11
140	Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5982-5990.	3.2	10
141	Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2015, 2015, 3.	1.6	10
142	Age-Dependent Changes in Sirolimus Metabolite Formation in Patients With Neurofibromatosis Type 1. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 395-399.	1.0	10
143	Selumetinib in Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2017, 376, 1195-1195.	13.9	10
144	Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).. <i>Journal of Clinical Oncology</i> , 2021, 39, 10010-10010.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets. , 2012, , 445-467.		10
146	Attitudes About Internet Support Groups Among Adolescents and Young Adults with Neurofibromatosis Type 1 and their Parents. Journal of Genetic Counseling, 2014, 23, 796-804.	0.9	9
147	Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. Cancer Chemotherapy and Pharmacology, 2001, 48, 235-240.	1.1	8
148	SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST).. Journal of Clinical Oncology, 2014, 32, TPS10603-TPS10603.	0.8	8
149	Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta). Comparative Medicine, 2013, 63, 355-60.	0.4	8
150	PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1. Pediatric Blood and Cancer, 2013, 60, E166-E169.	0.8	7
151	Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 970, 95-101.	1.2	7
152	Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction. Pediatric Blood and Cancer, 2015, 62, 1512-1513.	0.8	6
153	Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions. Journal of the National Cancer Institute, 2017, 109, .	3.0	6
154	Developing therapies for rare tumors: opportunities, challenges and progress. Expert Opinion on Orphan Drugs, 2016, 4, 93-103.	0.5	5
155	Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromes. Neuro-Oncology Advances, 2020, 2, i134-i140.	0.4	5
156	Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas. Neurology, 2021, 97, S15-S24.	1.5	5
157	Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	5
158	Are Some Randomized Clinical Trials Impossible?. Journal of Pediatric Orthopaedics, 2021, 41, e90-e93.	0.6	5
159	Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1. Molecular Genetics & Genomic Medicine, 2020, 8, e1400.	0.6	4
160	Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. Neuro-Oncology Advances, 2021, 3, vdab020.	0.4	4
161	Editorial: Special issue on rare cancers. Current Problems in Cancer, 2021, 45, 100774.	1.0	4
162	Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinoma. Cancer Genetics, 2021, 256-257, 21-25.	0.2	4

#	ARTICLE	IF	CITATIONS
163	Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity.. Journal of Clinical Oncology, 2012, 30, 6530-6530.	0.8	4
164	Plasma and cerebrospinal fluid pharmacokinetics of selumetinib in non-human primates (NHP).. Journal of Clinical Oncology, 2017, 35, e14070-e14070.	0.8	4
165	Using a lower dose of glucarpidase to reduce plasma levels of methotrexate. Clinical Advances in Hematology and Oncology, 2013, 11, 324-5.	0.3	4
166	The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Cancer Chemotherapy and Pharmacology, 2012, 69, 247-252.	1.1	3
167	Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion. Pediatric Blood and Cancer, 2016, 63, 366-366.	0.8	3
168	Case report of adrenocortical carcinoma associated with double germline mutations in <i>MSH2</i> and <i>RET</i> . American Journal of Medical Genetics, Part A, 2021, 185, 1282-1287.	0.7	3
169	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	0.8	3
170	Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer. Blood, 2012, 120, 1497-1497.	0.6	3
171	Phase I trial and pharmacokinetic (PK) study of satraplatin in children and young adults with refractory solid tumors including brain tumors.. Journal of Clinical Oncology, 2013, 31, 2554-2554.	0.8	3
172	Immunogenicity and safety of glucarpidase for methotrexate toxicity.. Journal of Clinical Oncology, 2014, 32, e20648-e20648.	0.8	3
173	Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning. American Journal of Medical Genetics, Part A, 2022, 188, 488-497.	0.7	3
174	Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review. Operative Neurosurgery, 2022, 22, 44-50.	0.4	3
175	RESPONSE: Re: Treatment of Accidental Intrathecal Methotrexate Overdose. Journal of the National Cancer Institute, 2005, 97, 610-611.	3.0	2
176	Immune checkpoint inhibitors for refractory childhood cancers. Lancet Oncology, The, 2020, 21, 14-15.	5.1	2
177	Neurofibromatosis Clinical Trials-REINS Collaboration 2020 Recommendations. Neurology, 2021, 97, .	1.5	2
178	Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. Neurology, 2021, 97, S99-S110.	1.5	2
179	Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1. , 2012, , 625-657.		2
180	Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2019, , .		2

#	ARTICLE	IF	CITATIONS
181	Molecular mechanism(s) of resistance to vandetanib in medullary thyroid carcinoma.. Journal of Clinical Oncology, 2020, 38, e15628-e15628.	0.8	2
182	Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Current Oncology, 2021, 28, 4357-4366.	0.9	2
183	Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC). Children, 2022, 9, 774.	0.6	2
184	Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).. Journal of Clinical Oncology, 2022, 40, 11561-11561.	0.8	2
185	Merlin PAKs a Punch. Cancer Journal (Sudbury, Mass), 2004, 10, 8-11.	1.0	1
186	Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. Cancer Chemotherapy and Pharmacology, 2011, 67, 1291-1297.	1.1	1
187	RARE-07. THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1. Neuro-Oncology, 2018, 20, vi237-vi237.	0.6	1
188	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 10052-10052.	0.8	1
189	A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children's Oncology Group phase I consortium trial.. Journal of Clinical Oncology, 2014, 32, 10078-10078.	0.8	1
190	Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology, 2018, 36, 10540-10540.	0.8	1
191	Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with hepatic impairment.. Journal of Clinical Oncology, 2014, 32, 8547-8547.	0.8	1
192	Pharmacokinetics and Tolerability of Etoposide in Newly Diagnosed Lymphoma Patients with Hepatic Impairment. Blood, 2014, 124, 4445-4445.	0.6	1
193	Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity. European Journal of Paediatric Neurology, 2022, 38, 7-12.	0.7	1
194	Development of Targeted Therapies for Neurofibromatosis Type 1 (NF1) Related Tumors. , 2010, , 331-350.		0
195	Reply to P.A. Meyers et al. Journal of Clinical Oncology, 2011, 29, e181-e181.	0.8	0
196	Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies.. Journal of Clinical Oncology, 2018, 36, 2536-2536.	0.8	0
197	Diagnosis and Management of Benign Nerve Sheath Tumors in NF1: Evolution from Plexiform to Atypical Neurofibroma and Novel Treatment Approaches. , 2020, , 165-179.		0
198	Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2919-2928.	1.8	0

#	ARTICLE	IF	CITATIONS
199	Patient reported outcomes in adult patients with neuroendocrine neoplasms.. Journal of Clinical Oncology, 2022, 40, e24122-e24122.	0.8	0
200	Natural history study for children and adults with rare solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS1600-TPS1600.	0.8	0
201	Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials. Oncologist, 0, , .	1.9	0